Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 2/20 | 0.45 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.38 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | AKT1 | P31749 | 2/20 | 0.37 |
| ▸ | AKT2 | P31751 | 2/20 | 0.37 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | PDE4A | P27815 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30724619 | 1.00 | DHODH (0.45) | DHODHSLC40A1KDM4EMEN1KMT2A | |
| SCHEMBL9068281 | 0.88 | DHODH (0.40) | DHODHKDM4ENPC1AKT1AKT2 | |
| SCHEMBL28261532 | 0.79 | PDE10A (0.59) | DHODHKDM4EMEN1KMT2ALMNA | |
| SCHEMBL28083059 | 0.78 | TDP1 (0.45) | KDM4EMEN1KMT2ALMNANPC1 | |
| SCHEMBL12895010 | 0.77 | ALDH1A1 (0.40) | SLC40A1KDM4EMEN1KMT2ALMNA | |
| SCHEMBL12134726 | 0.77 | PSMB5 (0.41) | SLC40A1KDM4EMEN1KMT2ALMNA | |
| SCHEMBL361776 | 0.77 | AKT1 (0.49) | DHODHMEN1KMT2ALMNANPC1 | |
| SCHEMBL20081370 | 0.77 | PDE10A (0.61) | KDM4EMEN1KMT2ALMNANPC1 | |
| SCHEMBL9958654 | 0.76 | DHODH (0.49) | DHODHKDM4EMEN1KMT2ALMNA | |
| SCHEMBL1692394 | 0.76 | DHODH (0.44) | DHODHKDM4EMEN1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112778306-B | Synthesis method of 1, 8-naphthyridine derivative | 吉林化工学院 | 2024-01-26 | — | — | CN | disclosed |
| CN-112778306-A | Synthetic method of 1, 8-naphthyridine derivative | 吉林化工学院 | 2021-05-11 | — | — | CN | disclosed |
| EP-2655342-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | Amgen Inc. (US) | 2013-10-30 | — | — | EP | disclosed |
| US-20130267526-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN, INC. (CA) | 2013-10-10 | — | — | US | disclosed |
| US-20130267526-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN, INC. (CA) | 2013-10-10 | — | — | US | disclosed |
| US-20130267526-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN, INC. (CA) | 2013-10-10 | — | — | US | disclosed |
| WO-2012087784-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2012-06-28 | — | — | WO | disclosed |
| WO-2012087784-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2012-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130267526-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, BCL9, MALT1 | DHODH 2700/4885SLC40A1 4324/4885KDM4E 1545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.